Published on GHDx (https://ghdx.healthdata.org.)

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study

General Info

Geography 
Afghanistan (AFG)
Albania (ALB)
Algeria (DZA)
Angola (AGO)
Argentina (ARG)
Armenia (ARM)
Australia (AUS)
Austria (AUT)
Azerbaijan (AZE)
Bahamas (BHS)
Bahrain (BHR)
Bangladesh (BGD)
Barbados (BRB)
Belarus (BLR)
Belgium (BEL)
Belize (BLZ)
Benin (BEN)
Bhutan (BTN)
Bolivia (BOL)
Bosnia and Herzegovina (BIH)
Botswana (BWA)
Brazil (BRA)
Brunei Darussalam (BRN)
Bulgaria (BGR)
Burkina Faso (BFA)
Burundi (BDI)
Cabo Verde (CPV)
Cambodia (KHM)
Cameroon (CMR)
Canada (CAN)
Central African Republic (CAF)
Chad (TCD)
Chile (CHL)
China (CHN)
Colombia (COL)
Comoros (COM)
Congo (COG)
Costa Rica (CRI)
Croatia (HRV)
Cuba (CUB)
Cyprus (CYP)
Czechoslovakia (Czechia, Slovakia)
Czech Republic
Côte d'Ivoire (CIV)
Democratic Republic of the Congo (COD)
Denmark (DNK)
Djibouti (DJI)
Dominican Republic (DOM)
Ecuador (ECU)
Egypt (EGY)
El Salvador (SLV)
Equatorial Guinea (GNQ)
Eritrea (ERI)
Estonia (EST)
Eswatini (SWZ)
Ethiopia (ETH)
Fiji (FJI)
Finland (FIN)
France (FRA)
Gabon (GAB)
Gambia (GMB)
Georgia (GEO)
Germany (DEU)
Ghana (GHA)
Greece (GRC)
Grenada (GRD)
Guatemala (GTM)
Guinea (GIN)
Guinea-Bissau (GNB)
Guyana (GUY)
Haiti (HTI)
Honduras (HND)
Hungary (HUN)
Iceland (ISL)
India (IND)
Indonesia (IDN)
Iran (Islamic Republic of) (IRN)
Iraq (IRQ)
Ireland (IRL)
Israel (ISR)
Italy (ITA)
Jamaica (JAM)
Japan (JPN)
Jordan (JOR)
Kazakhstan (KAZ)
Kenya (KEN)
Kuwait (KWT)
Kyrgyzstan (KGZ)
Lao People's Democratic Republic (LAO)
Latvia (LVA)
Lebanon (LBN)
Lesotho (LSO)
Liberia (LBR)
Libya (LBY)
Lithuania (LTU)
Luxembourg (LUX)
Madagascar (MDG)
Malawi (MWI)
Malaysia (MYS)
Maldives (MDV)
Mali (MLI)
Malta (MLT)
Mauritania (MRT)
Mauritius (MUS)
Mexico (MEX)
Micronesia (Federated States of) (FSM)
Mongolia (MNG)
Montenegro (MNE)
Morocco (MAR)
Mozambique (MOZ)
Myanmar (MMR)
Namibia (NAM)
Nepal (NPL)
Netherlands (NLD)
New Zealand (NZL)
Nicaragua (NIC)
Niger (NER)
Nigeria (NGA)
North Macedonia (MKD)
Norway (NOR)
Oman (OMN)
Pakistan (PAK)
Panama (PAN)
Papua New Guinea (PNG)
Paraguay (PRY)
Peru (PER)
Philippines (PHL)
Poland (POL)
Portugal (PRT)
Qatar (QAT)
Republic of Korea (KOR)
Republic of Moldova (MDA)
Romania (ROU)
Russian Federation (RUS)
Rwanda (RWA)
Saint Lucia (LCA)
Saint Vincent and the Grenadines (VCT)
Samoa (WSM)
Sao Tome and Principe (STP)
Saudi Arabia (SAU)
Senegal (SEN)
Serbia (SRB)
Sierra Leone (SLE)
Singapore (SGP)
Slovakia (SVK)
Slovenia (SVN)
Solomon Islands (SLB)
Somalia (SOM)
South Africa (ZAF)
Spain (ESP)
Sri Lanka (LKA)
Sudan (SDN)
Suriname (SUR)
Sweden (SWE)
Switzerland (CHE)
Syrian Arab Republic (SYR)
Tajikistan (TJK)
Thailand (THA)
Timor-Leste (TLS)
Togo (TGO)
Tonga (TON)
Trinidad and Tobago (TTO)
Tunisia (TUN)
Turkmenistan (TKM)
Türkiye (TUR)
Uganda (UGA)
Ukraine (UKR)
United Arab Emirates (ARE)
United Kingdom (GBR)
United Republic of Tanzania (TZA)
United States of America (USA)
Uruguay (URY)
Uzbekistan (UZB)
Vanuatu (VUT)
Venezuela (Bolivarian Republic of) (VEN)
Viet Nam (VNM)
Yemen (YEM)
Zambia (ZMB)
Zimbabwe (ZWE)
View all
Time period covered 
January, 2012 - December, 2013
Data type
Scientific literature
Keywords 
HPV vaccines, Preventive interventions

Citation

Authors 
Jit M, Brisson M, Portnoy A, Hutubessy R
Journal 
Lancet Glob Health
Pages 
e406-14
Publication year 
2014
Suggested citation 
Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014; 2(7): e406-14.
Source URL:https://ghdx.healthdata.org./record/cost-effectiveness-female-human-papillomavirus-vaccination-179-countries-prime-modelling